CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and OlderGlobeNewsWire • 11/15/22
Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and OlderGlobeNewsWire • 11/15/22
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/08/22
Arcutis Announces Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/08/22
Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to DiagnosisGlobeNewsWire • 10/21/22
Arcutis Biotherapeutics: Keeping A Close Eye On Initial Launch Metrics For ZoryveSeeking Alpha • 09/29/22
Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body PsoriasisGlobeNewsWire • 09/26/22
Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque PsoriasisGlobeNewsWire • 09/20/22
New Data from Arcutis' STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) CongressGlobeNewsWire • 09/09/22
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 millionPRNewsWire • 09/08/22
New Data from Arcutis' Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) CongressGlobeNewsWire • 09/06/22
NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEINGPRNewsWire • 08/30/22
Wall Street Analysts Believe Arcutis Biotherapeutics, Inc. (ARQT) Could Rally 134%: Here's is How to TradeZacks Investment Research • 08/26/22
Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic DermatitisGlobeNewsWire • 08/23/22
Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured PatientsGlobeNewsWire • 08/22/22
Can Arcutis Biotherapeutics, Inc. (ARQT) Climb 123% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/10/22
Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and OlderGlobeNewsWire • 08/10/22
Arcutis Announces Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/22